DBVT insider reports share sales, 44K RSUs and 253K options

Rhea-AI Filing Summary

DBV Technologies S.A. (DBVT) reported insider transactions by its Chief Medical Officer on a Form 4. On November 20, 2025, the officer sold 6,496 ordinary shares at $2.88 per share, followed by a sale of 1,624 ordinary shares at $2.77 per share on November 21, 2025, mainly to cover tax withholding tied to vesting restricted stock units. After these sales, the officer held 101,529 ordinary shares directly, which then increased to 145,529 ordinary shares after the grant of new equity.

On November 21, 2025, the officer received 44,000 restricted stock units (RSUs), each representing one ordinary share, and an employee stock option for 253,000 ordinary shares with an exercise price of $2.90. Both the RSUs and options vest in four equal annual installments starting on November 21, 2026, subject to continued service. The filing notes that each American Depositary Share currently represents five ordinary shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mohideen Pharis

(Last) (First) (Middle)

C/O DBV TECHNOLOGIES S.A.

107, AVENUE DE LA REPUBLIQUE

(Street)

CHATILLON I0 92320

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DBV Technologies S.A. [ DBVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	11/20/2025		S(2)		6,496	D	$2.88(3)	103,153	D
Ordinary Shares(1)	11/21/2025		S(2)		1,624	D	$2.77(4)	101,529	D
Ordinary Shares(1)	11/21/2025		A(5)		44,000	A	$0	145,529	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$2.9(4)	11/21/2025		A		253,000		(6)	11/21/2035	Ordinary Shares	253,000	$0	253,000	D

Explanation of Responses:

1. The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares.

2. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.

3. This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.15268 to EURO 1.00 as of November 20, 2025.

4. This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.15154 to EURO 1.00 as of November 21, 2025.

5. Represents the Issuer's ordinary shares underlying a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one ordinary share. The RSUs shall vest in four equal annual installments commencing on November 21, 2026, subject to the Reporting Person continuing to provide service through each such date.

6. The option shall vest in four equal annual installments commencing on November 21, 2026, subject to the Reporting Person continuing to provide service through each such date.

	/s/ Virginie Boucinha, Attorney-in-Fact	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did DBV Technologies (DBVT) report on this Form 4?

The Chief Medical Officer of DBV Technologies S.A. (DBVT) reported sales of ordinary shares on November 20–21, 2025, the grant of new restricted stock units, and the grant of a stock option for ordinary shares.

How many DBV Technologies (DBVT) shares were sold and at what prices?

The officer sold 6,496 ordinary shares on November 20, 2025 at $2.88 per share and 1,624 ordinary shares on November 21, 2025 at $2.77 per share.

Why were some DBV Technologies (DBVT) shares sold in this filing?

The filing states that the shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units, rather than as open-market discretionary sales.

What new equity awards did the DBV Technologies (DBVT) officer receive?

The officer received a grant of 44,000 restricted stock units (RSUs) and an employee stock option for 253,000 ordinary shares with an exercise price of $2.90 per share.

How do the DBV Technologies (DBVT) RSUs and options vest?

Both the 44,000 RSUs and the 253,000-share stock option vest in four equal annual installments starting on November 21, 2026, subject to the officer continuing to provide service through each vesting date.

How many DBV Technologies (DBVT) shares does the officer own after these transactions?

After the reported transactions, the officer directly beneficially owned 145,529 ordinary shares of DBV Technologies S.A.

How are DBV Technologies (DBVT) ordinary shares related to American Depositary Shares (ADS)?

The filing explains that the company’s ordinary shares may be represented by American Depositary Shares, and that each ADS currently represents five ordinary shares.